3-D echocardiography does not reveal left atrial anatomy.

Rev Esp Cardiol. 2010;63(3):362-76 369 hypertension, and high pulmonary-capillary wedge pressure, may facilitate the risk of development of alveolar haemorrhage in patients treated with GP IIb/IIIa inhibitors, whereas others, believe that pulmonary disease does not necessarily define a subgroup of patients particularly at risk for this complication. The unpredictable and potentially lethal course of pulmonary blood loss requires prompt identification, airway protection, and correction of coagulopathy. Discontinuation of antiplatelet and anticoagulant agents and mechanical ventilation are the mainstay for the acute treatment of alveolar haemorrhage following GP IIb/IIIa inhibitors administration.2 The recognition of pulmonary alveolar haemorrhage requires a high degree of suspicion, particularly in patients presenting with dyspnoea, hypoxemia and/or chest radiographic abnormalities. Non specific symptoms and signs often delay or misidentify the diagnosis, thereby allowing fearful disease progression.5 The physicians should keep in mind this serious complication when they use antiplatelet GP IIb/IIIa inhibitors.